AG928

β Amyloid 1-42, aβ, Y10A, TFA, recombinant human

• UNSPSC Code: 51111800
• eCl@ss: 32160405
• NACRES: NA.41

Properties

• Assay: ≥98%
• Quality Level: 100
• UniProt accession no.: P05067
• Gene Information: human ... APP(351)

Description

Application

Different researchers claim enhanced activity due to different salts.



The TFA salt is what has been the industry standard.



The HFIP makes the beta-amyloid homogenously monomeric.



The NaOH apparently make it monomeric too and is also water soluble, which the TFA salt and HFIP are not.



The HCl salt is supposed to be more biological, as TFA is not found in the body.



By offering the different salts, it lets the researchers duplicate the different assays that have been developed by other researchers (see below).



TFA: Shu-chuan Jao, S-C, et. al. 1997, Amyloid; Int J Exp. Clinical Invest. 4, 231

HFIP: Stine, W.B. et. al. 2003, J. Biol. Chem, 278, 11612

NaOH: Fezoui, Y., et. al. 2000, Amyloid, 7, 166

HCL: Kanek, I and Tutumi, S., 1997, J. Neurochem, 68, 438

Physical form

White lyophilized powder. Resuspend in any one of the following solvents: 0.1% TFA, 5 mM HCl, 2 mM NaOH, 0.2% NH4OH at a concentration of 1 mg/mL. Sonicate for 30 seconds to 1 minute after it has gone into solution. To bring into your solution: After resuspension, add 5x or 10x buffer stock (PBS, TBS) and water to bring to 1x buffer.

Storage and Stability

Maintain lyophilized material at -20°C for up to 12 months after date of receipt. After reconstitution maintain at -20°C to -70°C for up to 2 weeks in undiluted aliquots. Avoid freeze/thaw cycles to avoid aggregation.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.